{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:24:26Z","timestamp":1778189066796,"version":"3.51.4"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>As hematopoietic progenitors supply a large number of blood cells, therapeutic strategies targeting hematopoietic progenitors are potentially beneficial to eliminate unwanted blood cells, such as leukemic cells and immune cells causing diseases. However, due to their pluripotency, targeting those cells may impair the production of multiple cell lineages, leading to serious side effects such as anemia and increased susceptibility to infection. To minimize those side effects, it is important to identify monopotent progenitors that give rise to a particular cell lineage. Monocytes and monocyte-derived macrophages play important roles in the development of inflammatory diseases and tumors. Recently, we identified human monocyte-restricted progenitors, namely, common monocyte progenitors and pre-monocytes, both of which express high levels of CD64, a well-known monocyte marker. Here, we introduce a dimeric pyrrolobenzodiazepine (dPBD)-conjugated anti-CD64 antibody (anti-CD64-dPBD) that selectively induces the apoptosis of proliferating human monocyte-restricted progenitors but not non-proliferating mature monocytes. Treatment with anti-CD64-dPBD did not affect other types of hematopoietic cells including hematopoietic stem and progenitor cells, neutrophils, lymphocytes and platelets, suggesting that its off-target effects are negligible. In line with these findings, treatment with anti-CD64-dPBD directly killed proliferating monocytic leukemia cells and prevented monocytic leukemia cell generation from bone marrow progenitors of chronic myelomonocytic leukemia patients in a patient-derived xenograft model. Furthermore, by depleting the source of monocytes, treatment with anti-CD64-dPBD ultimately eliminated tumor-associated macrophages and significantly reduced tumor size in humanized mice bearing solid tumors. Given the selective action of anti-CD64-dPBD on proliferating monocyte progenitors and monocytic leukemia cells, it should be a promising tool to target cancers and other monocyte-related inflammatory disorders with minimal side effects on other cell lineages.<\/jats:p>","DOI":"10.3389\/fimmu.2021.618081","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T04:14:21Z","timestamp":1613967261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["An Antibody-Drug Conjugate That Selectively Targets Human Monocyte Progenitors for Anti-Cancer Therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuta","family":"Izumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongchuzi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikage","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Ohteki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0215-y","article-title":"Update on the pathologic diagnosis of chronic myelomonocytic leukemia","volume":"32","author":"Arber","year":"2019","journal-title":"Mod Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00509-9","article-title":"Chronic myelomonocytic leukemia: 2018 update to prognosis and treatment","volume":"14","author":"Elmariah","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B5","article-title":"Prognosis of chronic myelomonocytic leukemia","volume":"81","author":"Catalano","year":"1996","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23962","article-title":"Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4062\/biomolther.2015.116","article-title":"Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics","volume":"23","author":"Kim","year":"2015","journal-title":"Biomol Ther (Seoul)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"Biomark Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4892(03)00083-3","article-title":"Antibody-targeted chemotherapy with immunoconjugates of calicheamicin","volume":"3","author":"Damle","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"key":"B12","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.immuni.2017.04.019","article-title":"Identification of a human clonogenic progenitor with strict monocyte differentiation potential: A counterpart of mouse cMoPs","volume":"46","author":"Kawamura","year":"2017","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.7405","article-title":"Expression of Tie-2 by human monocytes and their responses to angiopoietin-2","volume":"178","author":"Murdoch","year":"2007","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-053504","article-title":"Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer","volume":"109","author":"Venneri","year":"2007","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eaat1500","DOI":"10.1126\/scitranslmed.aat1500","article-title":"Human tumor-associated monocytes\/macrophages and their regulation of T cell responses in early-stage lung cancer","volume":"11","author":"Singhal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.04.010","article-title":"Progress in tumor-associated macrophage (TAM)-targeted therapeutics","volume":"114","author":"Ngambenjawong","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2217\/nnm.14.13","article-title":"Macrophages associated with tumors as potential targets and therapeutic intermediates","volume":"9","author":"Vinogradov","year":"2014","journal-title":"Nanomed (Lond)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00188","article-title":"Tumor-associated macrophages: Recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163","article-title":"Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma","volume":"16","author":"Ao","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-019-00745-z","article-title":"A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors","volume":"38","author":"Lee","year":"2020","journal-title":"Invest New Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.300168","article-title":"Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions","volume":"33","author":"Mantovani","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J Cell Physiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00152","article-title":"Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice","volume":"9","author":"Hanazawa","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.4049\/jimmunol.155.10.4996","article-title":"Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody","volume":"155","author":"Graziano","year":"1995","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.139.10.3536","article-title":"Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells","volume":"139","author":"Graziano","year":"1987","journal-title":"J Immunol"},{"key":"B32","article-title":"inventors\/applicants (for US only); Medarex, Inc., applicant (for all designated States except US). Human Monoclonal Antibodies to Fc Gamma Receptor I (CD64). International patent WO 2006\/002438 A3","author":"Graziano","year":"2006"},{"key":"B33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/protein\/gzx067","article-title":"Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability","volume":"31","author":"Sussman","year":"2018","journal-title":"Protein Eng Des Sel"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400782101","article-title":"A gene atlas of the mouse and human protein-encoding transcriptomes","volume":"101","author":"Su","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biomedicines5030056","article-title":"CD64: An attractive immunotherapeutic target for M1-type macrophage mediated chronic inflammatory diseases","volume":"5","author":"Akinrinmade","year":"2017","journal-title":"Biomedicines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(90)90613-p","article-title":"Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain","volume":"39","author":"Bai","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0229027","DOI":"10.1371\/journal.pone.0229027","article-title":"R409K mutation prevents acid-induced aggregation of human IgG4","volume":"15","author":"Namisaki","year":"2020","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12030","article-title":"PMA withdrawal in PMA-treated monocytic THP-1 cells and subsequent retinoic acid stimulation, modulate induction of apoptosis and appearance of dendritic cells","volume":"46","author":"Spano","year":"2013","journal-title":"Cell Prolif"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13519","article-title":"Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology","volume":"22","author":"Bill","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells","volume":"100","author":"Ito","year":"2002","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2010.02.008","article-title":"Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy","volume":"47","author":"Van Gorp","year":"2010","journal-title":"Mol Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ijc.28335","article-title":"Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse","volume":"134","author":"Reinartz","year":"2014","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01761","article-title":"A novel, five-marker alternative to CD16-CD14 gating to identify the three human monocyte subsets","volume":"10","author":"Ong","year":"2019","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr792","article-title":"Reduction of activated macrophages after ischaemia-reperfusion injury diminishes oxidative stress and ameliorates renal damage","volume":"27","author":"Fet","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2016.4","article-title":"Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages","volume":"94","author":"Hristodorov","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11568","article-title":"CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo","volume":"7","author":"Mladenov","year":"2016","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09824.x","article-title":"Recombinant, ETA\u2019-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice","volume":"163","author":"Ribbert","year":"2010","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.08.005","article-title":"Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells","volume":"341","author":"Schiffer","year":"2013","journal-title":"Cancer Lett"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25766","article-title":"In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA\u2019 in a human acute myeloid leukemia xenograft tumor model","volume":"129","author":"Tur","year":"2011","journal-title":"Int J Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.06.005","article-title":"Combinatorial single-cell analyses of granulocyte-monocyte progenitor heterogeneity reveals an early uni-potent neutrophil progenitor","volume":"53","author":"Kwok","year":"2020","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.celrep.2018.07.097","article-title":"Identification of an early unipotent neutrophil progenitor with pro-tumoral activity in mouse and human bone marrow","volume":"24","author":"Zhu","year":"2018","journal-title":"Cell Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"229ra40","DOI":"10.1126\/scitranslmed.3007696","article-title":"Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss","volume":"6","author":"Moutsopoulos","year":"2014","journal-title":"Sci Transl Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.01.011","article-title":"Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17","volume":"22","author":"Stark","year":"2005","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.10","article-title":"Neutrophils as protagonists and targets in chronic inflammation","volume":"17","author":"Soehnlein","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.immuni.2017.08.018","article-title":"Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression","volume":"47","author":"Zhu","year":"2017","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.618081\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T17:57:41Z","timestamp":1697911061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.618081\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2021.618081"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.618081","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"article-number":"618081"}}